Endo Launches Spatial Computing Simulator to Create a Fully Immersive Learning Environment for Hand Specialists
Endo (OTCQX: NDOI) has launched the Spatial Computing Injection Simulator, becoming the first pharmaceutical company to introduce an external spatial computing program. The simulator, utilizing Apple Vision Pro technology, creates an immersive learning environment for hand specialists administering XIAFLEX®, the only FDA-approved nonsurgical treatment for Dupuytren's contracture.
The 20-minute experience combines physical hand models with digital content, allowing healthcare providers to practice reconstitution, injection angles, and post-injection procedures. The technology has already garnered significant interest at medical conferences, with over 600 hand specialists testing it at the American Society for Surgery of the Hand (ASSH) and American Association for Hand Surgery (AAHS) annual meetings.
The simulator is now available through Endo's orthopedics sales team, developed in partnership with technology agency Lucid Dream for the Apple Vision Pro platform.
Endo (OTCQX: NDOI) ha lanciato il Simulatori di Iniezione per la Computazione Spaziale, diventando la prima azienda farmaceutica a introdurre un programma di computazione spaziale esterna. Il simulatore, che utilizza la tecnologia Apple Vision Pro, crea un ambiente di apprendimento immersivo per gli specialisti delle mani che somministrano XIAFLEX®, l'unico trattamento non chirurgico approvato dalla FDA per la contrattura di Dupuytren.
L'esperienza di 20 minuti combina modelli fisici delle mani con contenuti digitali, permettendo ai fornitori di assistenza sanitaria di esercitarsi nella ricostituzione, negli angoli di iniezione e nelle procedure post-iniezione. La tecnologia ha già suscitato un notevole interesse durante le conferenze mediche, con oltre 600 specialisti delle mani che l'hanno testata durante i congressi annuali della American Society for Surgery of the Hand (ASSH) e della American Association for Hand Surgery (AAHS).
Il simulatore è ora disponibile attraverso il team di vendita ortopedica di Endo, sviluppato in collaborazione con l'agenzia tecnologica Lucid Dream per la piattaforma Apple Vision Pro.
Endo (OTCQX: NDOI) ha lanzado el Simulador de Inyección de Computación Espacial, convirtiéndose en la primera empresa farmacéutica en introducir un programa externo de computación espacial. El simulador, que utiliza la tecnología Apple Vision Pro, crea un entorno de aprendizaje inmersivo para los especialistas en manos que administran XIAFLEX®, el único tratamiento no quirúrgico aprobado por la FDA para la contractura de Dupuytren.
La experiencia de 20 minutos combina modelos físicos de manos con contenido digital, permitiendo a los proveedores de atención médica practicar la reconstitución, los ángulos de inyección y los procedimientos posteriores a la inyección. La tecnología ya ha generado un interés significativo en conferencias médicas, con más de 600 especialistas en manos probándola en las reuniones anuales de la American Society for Surgery of the Hand (ASSH) y la American Association for Hand Surgery (AAHS).
El simulador ya está disponible a través del equipo de ventas de ortopedia de Endo, desarrollado en asociación con la agencia tecnológica Lucid Dream para la plataforma Apple Vision Pro.
Endo (OTCQX: NDOI)는 공간 컴퓨팅 주사 시뮬레이터를 출시하여 외부 공간 컴퓨팅 프로그램을 도입한 최초의 제약 회사가 되었습니다. 이 시뮬레이터는 Apple Vision Pro 기술을 활용하여 XIAFLEX®를 투여하는 손 전문의들을 위한 몰입형 학습 환경을 만듭니다. 이는 FDA에서 승인한 유일한 비수술적 Dupuytren 수축 치료제입니다.
20분 동안의 경험은 물리적인 손 모델과 디지털 콘텐츠를 결합하여 의료 제공자가 재구성, 주사 각도 및 주사 후 절차를 연습할 수 있도록 합니다. 이 기술은 이미 의료 회의에서 상당한 관심을 얻었으며, 600명 이상의 손 전문의가 American Society for Surgery of the Hand (ASSH)와 American Association for Hand Surgery (AAHS) 연례 회의에서 이를 테스트했습니다.
시뮬레이터는 이제 Endo의 정형외과 영업팀을 통해 제공되며, Apple Vision Pro 플랫폼을 위해 기술 에이전시 Lucid Dream과 협력하여 개발되었습니다.
Endo (OTCQX: NDOI) a lancé le Simulateur d'Injection en Informatique Spatiale, devenant ainsi la première entreprise pharmaceutique à introduire un programme externe d'informatique spatiale. Le simulateur, utilisant la technologie Apple Vision Pro, crée un environnement d'apprentissage immersif pour les spécialistes de la main administrant XIAFLEX®, le seul traitement non chirurgical approuvé par la FDA pour la contracture de Dupuytren.
L'expérience de 20 minutes combine des modèles physiques de mains avec du contenu numérique, permettant aux prestataires de soins de santé de s'exercer à la reconstitution, aux angles d'injection et aux procédures post-injection. La technologie a déjà suscité un intérêt considérable lors de conférences médicales, avec plus de 600 spécialistes de la main l'ayant testée lors des réunions annuelles de l'American Society for Surgery of the Hand (ASSH) et de l'American Association for Hand Surgery (AAHS).
Le simulateur est désormais disponible via l'équipe de vente en orthopédie d'Endo, développé en partenariat avec l'agence technologique Lucid Dream pour la plateforme Apple Vision Pro.
Endo (OTCQX: NDOI) hat den Spatial Computing Injektionssimulator eingeführt und ist damit das erste Pharmaunternehmen, das ein externes Programm für räumliches Rechnen einführt. Der Simulator nutzt die Technologie von Apple Vision Pro und schafft eine immersive Lernumgebung für Handchirurgen, die XIAFLEX® verabreichen, die einzige von der FDA zugelassene nicht-chirurgische Behandlung für die Dupuytren-Kontraktur.
Die 20-minütige Erfahrung kombiniert physische Handmodelle mit digitalen Inhalten, sodass Gesundheitsdienstleister das Rekonstituieren, die Injektionswinkel und die Nachsorge nach der Injektion üben können. Die Technologie hat bereits erhebliches Interesse auf medizinischen Konferenzen geweckt, wobei über 600 Handchirurgen sie bei den Jahrestagungen der American Society for Surgery of the Hand (ASSH) und der American Association for Hand Surgery (AAHS) getestet haben.
Der Simulator ist jetzt über das orthopädische Vertriebsteam von Endo erhältlich und wurde in Zusammenarbeit mit der Technologieagentur Lucid Dream für die Apple Vision Pro Plattform entwickelt.
- First-mover advantage in pharmaceutical industry with spatial computing technology
- Strong initial reception with 600+ healthcare providers testing the simulator
- Enhanced training tool for XIAFLEX®, the only FDA-approved nonsurgical treatment for Dupuytren's contracture
- None.
- Endo is the first pharmaceutical company to launch an external spatial computing program.
- The Spatial Computing Injection Simulator allows hand specialists to interact simultaneously with both physical and digital objects—blending a physical hand model and digital content via an Apple Vision Pro app—to help refine their injection technique.
- All members of Endo's orthopedics sales team are able to offer the experience to healthcare providers.
Experience the interactive Multimedia News Release here: https://www.multivu.com/endo/9322451-en-endo-launches-spatial-computing-injection-simulator-for-xiaflex
"The Spatial Computing Injection Simulator represents a major leap forward in enhancing patient care through a groundbreaking educational tool," said Justin Mattice, Senior Vice President & General Manager, Branded Specialty at Endo. "We're proud to pioneer this capability in the pharmaceutical industry, paving the way for future innovations that will help transform how healthcare professionals learn and gain hands-on experience."
Endo designed the Spatial Computing Injection Simulator to help hand specialists refine their injection technique in the hand for the administration of XIAFLEX® (collagenase clostridium histolyticum), the only FDA-approved nonsurgical treatment for Dupuytren's contracture when a "cord" can be felt.
Do not receive XIAFLEX® if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX®, or to any other collagenase product.
The Experience
The Spatial Computing Injection Simulator allows providers to interact with both physical objects and digital content simultaneously via a lifelike hand simulator model and an Apple Vision Pro app.
During the immersive, 20-minute experience, hand specialists receive "hands on" practice on reconstitution and injection angles, watch procedures in action, practice their injection technique on the hand model, and acquire information on the post-injection process.
This can help them refine their technique for the treatment of real patients with XIAFLEX, which is injected into the collagen "cord" causing the hand contracture.1
XIAFLEX represents an important treatment option to help appropriate patients.1
Early Reactions and Reviews
Endo recently previewed the technology at two premier medical conferences and generated interest and buzz for the program. At both the American Society for Surgery of the Hand (ASSH) and American Association for Hand Surgery (AAHS) annual meetings, healthcare providers lined up to try on the headsets and test their injection technique. In total, more than 600 hand specialists used the Spatial Computing Injection Simulator during the previews.
"Technology like this can make a huge difference for a hand surgeon or advanced practice provider in treating Dupuytren's contracture nonsurgically," said Dr. Jason Fanuele, an orthopedic surgeon who specializes in hand and upper extremity. "In my practice, we value a hands-on approach to learning, and this is the next-best thing to actually doing an injection in someone's hand—maybe even better thanks to the educational resources and context."
Now, all members of Endo's orthopedics sales team are able to offer the experience to healthcare providers.
Endo worked with technology agency Lucid Dream to create the Apple Vision Pro app and spatial computing experience.
About Dupuytren's Contracture
Dupuytren's contracture is a lifelong condition that may get worse over time. It's caused by a buildup of collagen in the hand, which forms a rope-like cord that pulls fingers toward the palm so they can't be straightened. As Dupuytren's contracture progresses, it may become difficult for individuals to use their hand(s) for daily tasks and activities.2,3 Dupuytren's contracture affects an estimated 17 million Americans.4,5*
WHAT IS XIAFLEX®?
XIAFLEX is a prescription medicine used to treat adults with Dupuytren's contracture when a "cord" can be felt. It is not known if XIAFLEX is safe and effective in children under the age of 18.
IMPORTANT SAFETY INFORMATION FOR XIAFLEX
Do not receive XIAFLEX if you have had an allergic reaction to collagenase clostridium histolyticum or any of the ingredients in XIAFLEX, or to any other collagenase product. See the end of the Medication Guide for a complete list of ingredients in XIAFLEX.
XIAFLEX can cause serious side effects, including:
- Tendon rupture or ligament damage. Receiving an injection of XIAFLEX may cause damage to a tendon or ligament in your hand and cause it to break or weaken. This could require surgery to fix the damaged tendon or ligament. Call your healthcare provider right away if you have trouble bending your injected finger (towards the wrist) after the swelling goes down or you have problems using your treated hand after your follow-up visit
- Nerve injury or other serious injury of the hand. After finger procedures, some people developed tears in the skin (lacerations), and local skin and soft-tissue necrosis (death of skin cells). Some lacerations and necrosis required skin grafting, or other surgery including amputation. Call your healthcare provider right away if you get numbness, tingling, increased pain, or tears in the skin (laceration) in your treated finger or hand after your injection or after your follow-up visit
- Hypersensitivity reactions, including anaphylaxis. Severe allergic reactions can happen in people who receive XIAFLEX because it contains foreign proteins. Call your healthcare provider right away if you have any of these symptoms of an allergic reaction after an injection of XIAFLEX:
- hives
- swollen face
- breathing trouble
- chest pain
- low blood pressure
- dizziness or fainting
- Fainting. Fainting (passing out) or near fainting can happen in people who receive XIAFLEX, especially following finger procedures
If you have dizziness or feel faint after receiving XIAFLEX, lie down until the symptoms go away. - Increased chance of bleeding. Bleeding or bruising at the injection site can happen in people who receive XIAFLEX. Talk to your healthcare provider if you have a problem with your blood clotting. XIAFLEX may not be right for you.
Before receiving XIAFLEX, tell your healthcare provider if you have had an allergic reaction to a previous XIAFLEX injection, or have a bleeding problem or any other medical conditions. Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. Using XIAFLEX with certain other medicines can cause serious side effects. Especially tell your healthcare provider if you take medicines to thin your blood (anticoagulants). If you are told to stop taking a blood thinner before your XIAFLEX injection, your healthcare provider should tell you when to restart the blood thinner. Ask your healthcare provider or pharmacist for a list of these medicines if you are unsure.
The most common side effects with XIAFLEX for the treatment of Dupuytren's contracture include:
- swelling of the injection site or the hand
- bruising or bleeding at the injection site
- pain or tenderness of the injection site or the hand
- swelling of the lymph nodes (glands) in the elbow or armpit
- itching
- breaks in the skin
- redness or warmth of the skin
- pain in the armpit
Tell your healthcare provider if you have any side effect that bothers you or does not go away. These are not all of the possible side effects with XIAFLEX. For more information, ask your healthcare provider or pharmacist.
Rx Only
Click for full Prescribing Information, including Medication Guide.
About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Mr. Mattice and Dr. Fanuele and any statements relating to product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect Endo's current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which Endo may not currently be able to predict. Although Endo believes that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, the following: changes in competitive, market or regulatory conditions; changes in legislation or regulations; the ability to obtain and maintain adequate protection for intellectual property rights; the impacts of competition; the timing and uncertainty of the results of the research and development and the regulatory processes; health care and cost containment reforms, including government pricing, tax and reimbursement policies; litigation and other disputes; consumer and physician acceptance of current and new products; the performance of third parties upon whom we rely for goods and services; issues associated with our supply chain; the ability to develop and expand our product pipeline, to launch new products and to continue to develop the market for our products; and the effectiveness of advertising and other promotional campaigns. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in press releases issued by Endo and in Endo's public filings with the
*Dupuytren's contracture prevalence estimation calculation: average Dupuytren's contracture prevalence in the US (
References
- XIAFLEX® [Prescribing Information].
Rochester, MI : EndoUSA , Inc. - Hurst LC, Badalamente MA, Hentz VR, et al. N Engl J Med. 2009;361(10),968-979.
- Bayat A, McGrouther DA. Management of Dupuytren's disease--clear advice for an elusive condition. Ann R Coll Surg Engl. 2006;88(1):3-8.
- "How common is Dupuytren disease?" Dupuytren Research Group. April 1, 2017. Accessed January 13, 2025. https://dupuytrens.org/faq
- "
U.S. and world population clock."U.S. Census Bureau. Updated April 13, 2023. Accessed January 13, 2025. https://www.census.gov/popclock
View original content:https://www.prnewswire.com/news-releases/endo-launches-spatial-computing-simulator-to-create-a-fully-immersive-learning-environment-for-hand-specialists-302411432.html
SOURCE Endo, Inc.
FAQ
What is the Spatial Computing Injection Simulator launched by Endo (NDOI)?
How long is the training session with Endo's (NDOI) Spatial Computing Simulator?
How many healthcare providers have tested Endo's (NDOI) new simulator at medical conferences?
Who can access Endo's (NDOI) Spatial Computing Injection Simulator?
